No Data
No Data
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Chengdu Easton Biopharmaceuticals (688513.SH): Dihydroxypropyltobramycin injection has obtained the Pharmaceutical registration certificate.
Chengdu Easton Biopharmaceuticals (688513.SH) announced that the company recently received notification from the National Medical Products Administration (referred to as "National Drug...
Chengdu Easton Biopharmaceuticals (688513.SH): is currently constructing an AI drug research and development assistance platform.
On March 3, Gelonghui reported that Chengdu Easton Biopharmaceuticals (688513.SH) stated on the interactive platform that the company has always focused on the application potential of AI large models as efficiency tools. Employees are encouraged to enhance work efficiency through the reasonable use of AI tools. Additionally, the company is currently constructing an AI-assisted drug development platform, planning to gradually launch functional modules within the year. The planned functions include virtual screening (molecular docking), similarity search, substructure search, molecular generation, patent filtering, and evaluation of molecular drugability.
Yuandong Biology: Yuandong Biology: 2024 Annual Results Express Announcement
Yuandong Biology: 2024 Annual Results Express Announcement